AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
February 25, 2021 16:05 ET
|
AnaptysBio, Inc.
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated...
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
November 13, 2020 09:25 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
November 04, 2020 16:00 ET
|
AnaptysBio, Inc.
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 FDA end-of-Phase 2 meeting anticipated in...
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
October 26, 2020 08:00 ET
|
AnaptysBio, Inc.
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020Additional 1% royalty to AnaptysBio on GSK’s...
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
October 13, 2020 09:00 ET
|
AnaptysBio, Inc.
6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29FDA...
AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference
September 11, 2020 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates
August 10, 2020 08:05 ET
|
AnaptysBio, Inc.
Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company...
AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps
August 10, 2020 08:00 ET
|
AnaptysBio, Inc.
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysisSecondary analyses demonstrated NPS and blood eosinophil...
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
August 05, 2020 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...